Rituximab and infliximab desensitization with anti-IgE mAb omalizumab as adjuvant therapy: a case series

Perlato, Margherita; Mecheri, Valentina; Accinno, Matteo; Vivarelli, Emanuele; Matucci, Andrea; Vultaggio, Alessandra

doi:10.1016/j.jaip.2022.08.036

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omalizumab has also been successfully used as adjuvant treatment in desensitization to chemotherapeutic drugs (i.e., carboplatin and oxaliplatin) in those patients experiencing breakthrough IgE-mediated reactions during desensitization protocol [ 129 , 130 , 131 , 132 , 133 , 134 , 135 ]. It has also been used to prevent hypersensitivity reactions to monoclonal antibodies (infliximab and rituximab) during desensitization [ 136 , 137 ]. Omalizumab could help reduce the impact of breakthrough reactions or even prevent reactions during desensitization by depowering mast cells and basophils.…”

Section: Prevention Of Allergymentioning

confidence: 99%

Therapeutical Targets in Allergic Inflammation

2022

View full text Add to dashboard Cite

From the discovery of IgE to the in-depth characterization of Th2 cells and ILC2, allergic inflammation has been extensively addressed to find potential therapeutical targets. To date, omalizumab, an anti-IgE monoclonal antibody, and dupilumab, an anti-IL-4 receptor α monoclonal antibody, represent two pillars of biologic therapy of allergic inflammation. Their increasing indications and long-term follow-up studies are shaping the many different faces of allergy. At the same time, their limitations are showing the intricate pathogenesis of allergic diseases.

show abstract

Section: Prevention Of Allergymentioning

confidence: 99%

Therapeutical Targets in Allergic Inflammation

2022

View full text Add to dashboard Cite

show abstract

Infliximab/omalizumab/rituximab

2023

Reactions Weekly

View full text Add to dashboard Cite

Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions

Li,

Naisbitt,

Sun

et al. 2024

Clin Experimental Allergy

View full text Add to dashboard Cite

Biological agents are widely used across medicine, including for immune‐mediated skin conditions such as psoriasis and atopic dermatitis. When used to treat a relevant pathological process, they demonstrate impressive efficacy and credible safety, helping to achieve remission and improved function and quality of life. However, with their expanded use, awareness and understanding of adverse reactions to biologicals have also increased. Herein, we discuss the pathomechanism of adverse reactions to biological agents used to treat skin conditions and apply these to Pichler's classification system. This classification differentiates five distinct types, namely overstimulation (type α), hypersensitivity or immunogenicity (β), immunodeviation (γ), cross‐reactivity (δ) and nonimmunologic adverse reactions (ε). This classification covers most types of adverse reactions associated with use of biological agents and could be used to better understand the reaction pathogenesis and manage the clinical features of biological adverse effects.

show abstract

Rituximab and infliximab desensitization with anti-IgE mAb omalizumab as adjuvant therapy: a case series

Cited by 3 publications

References 12 publications

Therapeutical Targets in Allergic Inflammation

Therapeutical Targets in Allergic Inflammation

Infliximab/omalizumab/rituximab

Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions

Contact Info

Product

Resources

About